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2Abstract1
2
p14ARF is a tumor suppressor controlling a p53/Mdm2-dependent checkpoint in response to3
oncogenic signals. Here we demonstrate that p14ARF prevents cell growth through activation of4
ATM/ATR/CHK kinases whatever the p53 status, by a mechanism involving the recruitment of5
the Tip60 protein. Moreover, we show that endogenous p14ARF is induced following cell exposure6
to alkylating agents and cigarette smoke condensate. Importantly, we demonstrate that7
neutralization of either p14ARF or Tip60 prevents ATM/CHK2 activation in this context, and8
provide further evidence that a Tip60/p14ARF complex is induced in treated cells. Altogether these9
data demonstrate that p14ARF and Tip60 are two closely components of DNA damage pathways,10
and suggest a model in which a p14ARF/Tip60-mediated chromatin remodelling contribute to11
DNA damage checkpoints. Finally, and consistent with a role of p14ARF as a determinant of12
CHK2 phosphorylation in lung carcinogenesis, we find a strong correlation between p14ARF and13
phospho-CHK2(Thr68) protein expression in human lung tumors (p<0.003). Thus, p14ARF is a14
pivotal tumor suppressive protein which acts at the interface of both oncogenic and genotoxic15
signaling networks to prevent abnormal cell growth.16
17
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3Introduction1
2
The ARF protein (p14ARF in human; p19ARF in mouse) is encoded by the unusual3
INK4A/ARF locus situated in 9p21, a region frequently altered in numerous human tumors (33).4
Because p19ARF-null mice are highly tumor prone and die early in life, ARF has been proposed to5
be most important in tumor surveillance (20). Accordingly, we previously described a frequent6
loss of p14ARF in aggressive lung tumors (15). It is presently well known that ARF mediates a7
p53/Mdm2-dependent checkpoint that responds to oncogenic hyperproliferative signals (33). In8
addition, we and others have recently identified new p53- and/or Mdm2-independent functions of9
ARF (14, 17). In the light of these data, it is now admitted that ARF can delay cell cycle10
progression and induce apoptosis in a p53-dependent as well as p53-independent context.11
However, the signaling pathways involved in these effects remain poorly understood.12
The DNA damage signaling pathway is an essential process that is activated following13
exposure to numerous types of genotoxic stresses and serves to influence or achieve DNA repair,14
cell cycle delay and/or apoptosis, in order to maintain genomic stability (42). Two members of15
the phosphatidylinositol 3-kinase-related kinase (PIKK) family, ATM (for Ataxia Telangiectasia16
Mutated) and ATR (for Ataxia Telangiectasia and Rad3-related), play a central role in DNA17
damage recognition and initial related-phosphorylation events (for reviews, see (32)). In response18
to genotoxic aggression, both ATM and ATR kinases are activated and further induce the19
recruitment and phosphorylation of a large number of proteins including the CHK1 and CHK220
kinases (for reviews, see (34)), which in turn phosphorylate unique and/or overlapping21
downstream targets such as p53, E2F1, Mdm2, Cdc25A, Cdc25c or Tlk1/2 proteins (for review,22
see (3)). Ultimately, this cascade of phosphorylations leads to a cell cycle arrest/delay in G1, S, or23
4G2, DNA repair, apoptosis or chromatin remodelling, depending on the cellular context.1
Therefore, CHK1 and CHK2 act as key transducers of proximal signals mediated by ATM and2
ATR. Several mechanisms have been involved in the activation of ATM/ATR signaling3
pathways. The best understood is the genesis of single or double DNA strand breaks. In this4
context, ATM preferentially responds to DNA double strand breaks that occur following5
radiation or treatments with chemotherapeutic agents whereas ATR is activated following6
exposure to other forms of damage such as bulky lesions or stalled replication forks (24).7
Moreover, it was also shown that telomere attrition induces a DNA damage response in8
mammalian cells (36). In agreement, senescent human fibroblasts that express shortened9
telomeres contain activated forms of Chk1 and Chk2 and display molecular markers10
characteristic of cells bearing DNA double-strand breaks such as γH2AX and p53BP1 (11).11
Interestingly, some recent data have also demonstrated that chromatin-modifying drugs such as12
histone deacetylase inhibitors can drive a DNA damage response in the absence of DNA breaks13
notably by inducing auto-phosphorylation of ATM (2). These results indicate that changes in14
chromatin structure might be another way to activate ATM/ATR pathway.15
Since we previously demonstrated the ability of p14ARF to induce a G2 arrest in human16
lung carcinoma cell lines deprived of a functional p53 (14), we aimed to investigate the cellular17
signaling pathways involved in this process. Here, we demonstrate that human p14ARF responds to18
cells injuries caused by genotoxic stresses by inhibiting cell proliferation, regardless of the p5319
status. To do so, p14ARF activates a Tip60-dependent ATM/ATR/CHK signaling pathway leading20
to a G2 arrest. Furthermore, and consistent with a role of p14ARF as a determinant of CHK221
activation in lung carcinogenesis, we find that the status of both p14ARF and activated phospho-22
5CHK2(Thr68) is correlated in human lung tumors. Overall, our results identify p14ARF as a critical1
component of the DNA damage signaling pathway.2
3
Material and methods4
5
Cell lines, cell growth assay, plasmids and transfection6
H358, H1299 and A549 human lung carcinoma cell lines were cultured in 5% CO2 at 37°C in7
RPMI-1640 medium (GIBCO, Cergy Pontoise, France), supplemented with 10% (v/v) heat-8
inactivated FCS. Normal Human Bronchial Epithelial cells (NHBE, BioWhittaker, USA) were9
cultured in BEGM medium. COS cells and MRC5 human fibroblasts were cultured in DMEM10
(GIBCO) supplemented with 10%(v/v) heat-inactivated FCS. Stable p14ARF inducible clones were11
obtained as previously described (14). Expression of p14ARF was induced when cells were12
cultured in presence of 1 µg/ml doxycyclin. Clonogenic assays were performed as previously13
described (14). Transient transfections of A549, COS, MRC5, H358 cells and of stable p14ARF-14
inducible clones were carried out using Fugene 6 (Roche Diagnostic). Plasmids used in transient15
transfections were pcDNA3, pcDNA3-p14ARF, pcDNA3-HA-tagged-p14ARF1-65, pcDNA3-Myc-16
tagged-p14ARF66-132 and pcDNA3-HA-tagged Tip60. In some experiments geneticin (G418; 80017
µg/ml) was added to the media 48 hours post-transfection and cells were cultured for 4 additional18
days. Plasmid encoding GST-Cdc25C was obtained from Pr. Helen Piwinica-Worms (St Louis,19
MO).20
21
6Cell treatment1
Caffeine, cisplatine, cyclophosphamide monohydrate, etoposide and methanesulfonic acid methyl2
ester (MMS) were all purchased from Sigma (Saint Quentin Fallavier, France). Cigarette smoke3
condensate (CSC) was obtained by mechanically smoking cigarettes. The particulate phase of4
smoke was collected on glass fibre filters and the amount obtained determined by weight increase5
of the filter. CSC was prepared by dissolving the collected smokes particulates in dimethyl6
sulfoxide (DMSO) and aliquots were kept at –80°C. Stable p14ARF-inducible clones were co-7
treated during 72 hours with or without doxycyclin (1 µg/ml) in presence or absence of caffeine8
(2 to 4mM). Treatment with cyclophosphamide (10µM), doxorubicin (10µM), etoposide (10µM),9
MMS (10µM) or CSC (3 to 30µg/ml) was performed for 24 hours in H358 cells.10
11
Antibodies12
The anti-Cdc2 p34 (sc-54), anti-Chk1 (G-4), anti-Mdm2 (SMP14), anti-Chk2 (H-300), anti-HA13
(sc805), anti-p14ARF (C-20) antibodies were purchased from santa Cruz, the anti-Mdm2 (Ab-2,14
clone 2A10), anti-p14ARF (Ab-2), anti-ATM (Ab-1), anti-ATR (Ab-2), anti-p14ARF (Ab-1), anti-15
Hsp70 (clone JG1, ABR) from Oncogene Research, the anti-phospho-ATM(Ser1981), anti-16
phospho-p53 (Ser15) (16G8), anti-phospho-(Ser/Thr) ATM/ATR substrate, anti-phospho-Cdc217
(Tyr15), anti-phospho-Cdc25c (Ser216), anti-phospho-Chk1 (Ser345), anti-phospho-Chk218
(Thr68), anti-phospho-p53(Ser20), anti-phospho-Rad17 (Ser645), anti-Rad17 from Cell19
signaling, the anti-Cdc25c (67211A) from Pharmingen, the anti-p53 (clone DO-7) from Dako,20
the anti-phospho-Histone H2A.X (Ser139) (clone JBW301) from Upstate, the anti-myc (clone21
9E10) from Roche Diagnostic and the anti-actin (20-33) from Sigma. Anti-Tip60 antibody was22
kindly provided by B Amati.23
7Transfection of siRNA oligonucleotides1
The sequences designed to target specifically human p14ARF, chk1, chk2, atm, atr and tip60 RNAs2
were as follow: p14ARF: 5’-GAACAUGGUGCGCAGGUUCTT-3’; chk1: 5’-3
GAAGCAGUCGCAGUGAAGATT-3’; chk2: 5’-GAACCUGAGGACCAAGAACTT-3’; atm:4
5’-GCGCCUGAUUCGAGAUCCUTT-3’; atr: 5’-CCUCCGUGAUGUUGCUUGATT-3’, tip60 :5
5’-AAGAAGAUCCAGUUCCCCAAGTT-3’ The scrambled siRNA oligonucleotides used as6
control for all  RNA interference experiments were as follow: 5’-7
AAAGGUGACGCUGACGAAGTT-3’; 5’-CAAGAAAGGCCAGUCCAAGTT-3’. Cells were8
transfected with siRNA oligonucleotides duplex using jetSITM reagent (Polyplus transfection,9
Illkirch, France). Doxycyclin (1 µg/ml) was added or not in the culture medium 4 hours after10
transfection. The cells were analyzed 72 hours post-transfection. For experiments with alkylating11
agents, cells were transfected for 48 hours with mismatch or p14ARF siRNAs, then alkylating12
agents were added for 24 additional hours.13
14
Cell cycle analysis15
Cells were washed twice in PBS and fixed in ice-cold ethanol for 10 min at –20°C. After two16
PBS washes, cells were incubated at 37°C for 10 min with 200U/ml of RNAse A (Sigma) and17
stained with propidium iodide (10 µg/ml in PBS). Cell-cycle distribution was determined by flow18
cytometry using the Cellfit software (Becton Dickinson, Grenoble, France).19
20
Immunoblotting and immunoprecipitation21
Immunoblotting and co-immunoprecipitation experiments were carried out as previously22
described (14, 27). CHK1/2 kinase assays were performed according to the protocol of Ahn and23
8Prives (1). Briefly, CHK1 or CHK2 was immunoprecipitated and incubated for 30 min at 30°C in1
the presence of 1-2µg GST or GST-Cdc25C fusion protein prepared according to the2
manufacturer’s protocol (Bulk GST Purification Module, Pharmacia Biotech). Immunoblotting3
was performed onto 10% SDS-PAGE and Cdc25C phosphorylation on its serine 216 residue was4
detected using a specific phospho-antibody. GST-fusion proteins were detected by5
immunoblotting using an anti-GST antibody.6
7
Indirect immunofluorescence8
Cells were then fixed in 2% paraformaldehyde/PBS for 5 min at room temperature, washed one9
time in PBS and permeabilized in 100% methanol for 20 min at –20°C. After extended washes,10
nonspecific binding sites were saturated in the presence of 1% BSA, 5% goat serum in PBS for11
45 min at RT and incubation was carried out with appropriate primary antibody. Cells were then12
incubated with AlexaTM 568 or AlexaTM 488 (Interchim), counterstained with Hoechst 33352 and13
observed using an Olympus microscope (x 40-60 magnification). Images were captured with a14
Coolview CCD camera (Photonic Science) and digitally saved using Visilog software.15
16
RT/PCR analyses17
Total cellular RNAs were isolated using Trizol reagent (Invitrogen) and reverse transcribed using18
oligo(dT) primer and M-MLV reverse transcriptase (Invitrogen) according to the manufacturer’s19
protocol. PCR was carried out for 30 cycles using the following conditions : 95°C for 30 sec ;20
58°C for Tip60 and 60°C for p14ARF for 1 min and 72°C for 1 min 30 sec. The primers used21
were : Tip60 forward (sense) 5’-AGGACAACGAAGATGAGTGG-3’ ; Tip60 reverse22
(antisense) 5’-CTCAATGTTCTTCATCCGGG-3’ , p14ARF forward (sense) 5’-23
9GAGAACATGGTGCGCAGG-3’,  p14ARF r e v e r s e  ( a n t i s e n s e )  5 ’ -1
TATGCGGGCATGGTTACTG-3’.  Amplification of a fragment of the cDNA of G3PDH2
(Invitrogen) was performed in the same PCR reaction as internal control. PCR products were run3
on a 2% agarose gel, visualized by ethidium bromide staining and quantified using the NIH4
Image software. For each case a Tip60/G3PDH or p14ARF/actin ratio was calculated to assess5
relative Tip60 or p14ARF mRNA expression level.6
7
GST pull-down assay8
GST pull-down assay was performed as previously described (13) using beads coated with either9
GST, GST-p14ARF, GST-p14ARF 1-65 or GST-p14ARF 66-132 fusion proteins and equivalent amounts of10
”in vitro” translated wild type or mutant Tip60 proteins.11
12
Tissue samples and immunohistochemistry (IHC)13
Seventy two lung tumor samples were obtained at surgical resection of primary lung tumor or14
diagnostic lymph node mediastinoscopy. The tumors were classified according to the 1999 World15
Health Organization (WHO) histological classification of lung tumors (38) and comprised 28 non16
small cell lung carcinomas (NSCLC; 9 adenocarcinoma, 19 squamous carcinoma) and 4417
neuroendocrine (NE) lung tumors (30 small cell lung carcinoma, 14 large cell neuroendocrine18
carcinoma). p14ARF immunostaining was carried out on cryosections of frozen samples using the19
anti-p14ARF (C-20) antibody as previously described (15). CHK2 and P- CHK2 (Thr68)20
immunostaining was performed on serial 3µm-thick paraffin sections using the Ventana21
Discovery Autostainer (Ventana Medical International Inc.Tuscon, AZ, USA). Non-immune22
mouse or rabbit sera were used as negative controls for all experiments. Immunostaining was23
10
interpreted independently by two observers. Scores of immunostaining were calculated by1
multiplying the percentage of labeled cells (from 0 to 100) with the intensity of staining (1+ to2
3+). Tumors with a score ≥ 20 were considered positive for p14ARF in accordance with our3
previous report (15). Non neoplastic fibroblasts and endothelial cells, as well as normal adjacent4
lung showing nuclear reactivity, were used as positive internal controls. Tumor samples5
exhibiting a total score ≥ 10 were considered positive for P-CHK2 (Thr 68) reactivity. As no6
internal positive staining was avaible for P-CHK2, its detection in some tumors of the same set of7
analysis was used as positive control. Tumors were considered positive for CHK2 expression8
when the overall score was ≥ 40. In this case, basal cells of normal bronchi showing nuclear9
staining were used as positive internal control.10
11
Results12
13
Caffeine prevents the G2 arrest induced by p14ARF14
We previously demonstrated the ability of p14ARF to induce a G2 arrest in a model of stable15
p14ARF-inducible clones derived from a p53-deficient H358 human lung adenocarcinoma cell line16
(14). To investigate the cellular signaling pathway(s) involved in this process, we first assessed17
the effect of various specific pharmacological inhibitors of MAP kinases, phosphatases and18
caffeine, on the antiproliferative capacity of p14ARF. We observed that treating cells with caffeine19
(4 mM), a known inhibitor of ATM/ATR/CHK kinases pathway, significantly reversed cell20
growth inhibition (Figure 1A), as well as G2 arrest (Figure 1B), induced by p14ARF.21
To further examine the caffeine effect on the p14ARF-induced G2 arrest, immunoblotting22
experiments were carried out. As shown in Figure 1C, a caffeine treatment prevented23
11
accumulation of both inactive phospho-Cdc2(Tyr15) and phospho-Cdc25c(Ser216) proteins,1
which had been previously detected in cells arrested in G2 upon p14ARF expression (14). Taken2
together, these data demonstrate that caffeine prevents the ability of p14ARF to induce a p53-3
independent G2 arrest, by acting upstream of Cdc2 and Cdc25c protein modifications.4
Furthermore they suggest that CHK kinases could be involved in the antiproliferative effect of5
p14ARF.6
7
p14ARF activates CHK1 and CHK2 to induce G2 arrest8
We first assessed CHK1 and/or CHK2 activation by p14ARF. In response to various types9
of DNA damage, CHK1 and CHK2 are activated by phosphorylation at serines 345/317 and at10
threonine 68 respectively (41). Interestingly, we reproducibly observed that p14ARF induced a11
mobility shift for both proteins, highly suggestive of their phosphorylation (Figure 2A, left12
panel). Accordingly, when specific phospho-antibodies were used, an accumulation of P-13
CHK1(Ser345) and P-CHK2(Thr68) products was detected in the presence of p14ARF, although14
the total CHK1/2 expression level did not vary. A similar activation of CHK1 and CHK2 was15
observed in MRC5 human fibroblasts transfected with a plasmid encoding p14ARF (Figure 2A,16
right panel). The ability of p14ARF to activate CHK1/2 was further confirmed by kinase assays17
using a recombinant GST-Cdc25C fusion protein as a direct substrate of CHK1/2 (Figure 2B).18
Taken together, these results demonstrate the ability of p14ARF to induce an activation of CHK119
and CHK2 in tumor as well as in primary cells.20
Then, we investigated the role of CHK1/2 activation on the antiproliferative activity of21
p14ARF. p14ARF-inducible cells were transfected with siRNA specifically targeting CHK1 and/or22
CHK2 and cell cycle profile was analyzed in the absence or presence of p14ARF induction.23
12
Consistent with previous data suggesting the requirement of CHK1 for normal G2/M transition1
(37), a significant increase in the proportion of G2 cells was observed in uninduced cells in which2
CHK1 was knocked down (Figure 3A). In addition, downregulation of CHK2 also faintly3
affected the cell cycle distribution in the absence of doxycyclin. Interestingly, the capacity of4
p14ARF to arrest cells in G2 was reduced in cells deprived of either CHK1 or CHK2 indicating that5
the CHK kinases are involved in the G2 checkpoint induced by p14ARF. More importantly, when6
the expression of both CHK1/2 kinases was inhibited, we observed the appearance of a7
population of cells with a sub-G1 DNA content in which apoptosis was confirmed by8
immunoblots detecting an active caspase-3 fragment (Figure 3B). Interestingly, a faint sub-G19
peak was also detected in the absence of p14ARF induction suggesting that inactivation of both10
kinases might be deleterious in proliferating cells. Of note, the concomittant transfection of Chk111
and Chk2 siRNAs allowed a complete inhibition of both proteins expression, as compared to12
transfection with either siRNA, suggesting that each protein could regulate the expression of the13
other. Overall, our results demonstrate that both CHK1 and CHK2 are required for p14ARF to14
restrain cell growth.15
16
p14ARF activates ATM/ATR pathways to mediate G2 arrest17
The most frequent pathway involved in activation of the CHK proteins is the well-known18
DNA damage response pathway, in which CHK1 and CHK2 act as downstream transducers of19
the ATM and ATR kinases (3). In this context, it was recently reported that ATM kinase is20
activated by autophosphorylation at serine 1981 (2). As shown in figure 4A, the accumulation of21
a P-ATM (Ser1981) product, which disappeared following a λ-phosphatase treatment prior to22
electrophoresis, was specifically detected upon p14ARF expression, indicating that p14ARF induces23
13
ATM activation. Interestingly, we also repeatedly noticed that p14ARF induction caused the1
appearance of a higher migrating band of ATR that shifted into a fast migrating one after2
treatment of the cellular extracts with λ-phosphatase suggesting ATR phosphorylation. Moreover,3
using an affinity-purified antibody recognizing the ATM/ATR phosphorylated consensus target4
sequence (phosphorylated pS/TQ), we also observed that p14ARF induced the accumulation or5
appearance of several ATM/ATR phosphorylated products, which disappeared upon a λ-6
phosphatase treatment. To go further, we analyzed whether p14ARF could induce the activation of7
two known ATM/ATR targets, namely the Rad17 and Histone H2AX proteins. In response to8
DNA damage, these two proteins are also rapidly phosphorylated onto their Ser645 and Ser1399
residues respectively (9, 44). In agreement with the data obtained with ATM/ATR (pS/TQ)10
antibody, accumulation of activated P-H2AX(Ser139) (γ-H2AX) and P-Rad17(Ser645) was11
observed upon p14ARF induction (Figure 4B). Furthermore, formation of numerous pS/TQ12
ATM/ATR, γ-H2AX and P-Rad17(Ser645) nuclear foci, strongly suggestive of DNA damage13
sites, were specifically observed in p14ARF-expressing cells (Figure 4C). Interestingly, we noticed14
that these nuclear foci did not colocalize with p14ARF staining, which was predominantly observed15
in the nucleoli, as previously described (14). In agreement with previous studies (35), we never16
detected accumulation of P-CHK1(Ser345) or P-CHK2(Thr68) proteins whithin nuclear foci in17
the same conditions (data not shown). Taken together, these results demonstrate that p14ARF18
induces the activation of ATM/ATR pathways.19
Finally, in order to analyze the requirement of ATM/ATR activation in the20
antiproliferative capacity of p14ARF, we performed siRNA experiments specifically targeting atm21
or atr. Our data showed that neutralization of either ATM or ATR strongly reduced the capacity22
of p14ARF to induce a G2 arrest (Figure 4D) and the accumulation of P-CHK1(Ser345) and P-23
14
Rad17(Ser645) proteins (Figure 4E). Interestingly, the phosphorylation of CHK2 on its Thr681
residue was specifically abrogated following ATM neutralization, whereas the phosphorylation of2
histone H2A.X was never affected (Figure 4E). Collectively, these results demonstrate that both3
ATM/ATR pathways are involved in the G2 checkpoint mediated by p14ARF in a p53-independent4
context.5
6
Activation of ATM/ATR signaling pathways by p14ARF is not restricted to p53-7
deficient cell lines8
Since we demonstrated the ability of p14ARF to activate ATM/ATR pathways in cells9
deprived of p53, we then asked whether this new p14ARF function might also be relevant in a more10
general context. Previous studies have reported that, in response to DNA-damaging agents, p53 is11
phosphorylated at Ser15 and Ser20 by ATM and CHK2 respectively (39). Similarly, MDM212
undergoes ATM-dependent phosphorylation (25). As shown in figure 5A, transfection of A54913
p53-proficient cells with a p14ARF expression vector induced the accumulation of both P-14
p53(Ser15) and P-p53(Ser20) products, as well as a slight increase of p53 level. Furthermore, a15
specific decrease in the 2A10 antibody reactivity, which monitors ATM-dependent MDM216
phosphorylation (25), was also clearly observed in p14ARF-expressing cells, although MDM2 was17
expressed at equivalent levels when detected with SMP14 antibody. Interestingly, similar results18
were obtained in our p14ARF-inducible clones (Figure 5B). Taken together, these data demonstrate19
that p14ARF activates the ATM/ATR signaling pathways whatever the p53 status.20
21
22
23
15
Tip60 is required for activation of the ATM/ATR pathway by p14ARF1
The Tip60 protein has been involved in DNA damage responses following gamma2
radiations (19). Interestingly, Tip60 was also recently ascribed to an ARF/p53 network (6).3
Altogether, these observations have led us to question whether Tip60 was involved in our model.4
To test this hypothesis, we studied by RNA interference the effects of Tip60 neutralization on the5
expression of ATR, P-ATM(Ser1981), P-CHK1(Ser345) and P-CHK2(Thr68) proteins in the6
p14ARF-inducible cell line. Since physiological Tip60 expression level is very low in these cells,7
we used RT/PCR to monitor the downregulation of Tip60. We found that neutralization of Tip608
prevented the activation by p14ARF of ATM, ATR, CHK1 and CHK2, as well as the9
phosphorylation of histone H2A.X (Figure 6), demonstrating that Tip60 is required for activation10
of the DNA damage pathway in response to p14ARF. Interestingly, we observed a stimulation of11
ATR and CHK1 phosphorylation when Tip60 was knocked-down in the absence of p14ARF12
induction. This suggests that Tip60 regulates CHK1 activation, which could be consistent with its13
involvement in G2/M transition (28). Thus, in order to distinguish between the intrinsic effect of14
Tip60 on cell cycle and its role in p14ARF-mediated activation of the DNA damage signaling15
pathway, we will focus our further studies on the ATM/CHK2 pathway which was not affected16
by Tip60 neutralization alone.17
18
p14ARF/Tip60 interaction is required for ATM/ATR activation19
Having established that Tip60 is involved in p14ARF-mediated activation of ATM/ATR,20
we investigated whether p14ARF could interact with Tip60. Using an in vitro pull down assay, we21
showed that in vitro translated HA-Tip60 was efficiently retained on GST-p14ARF beads,22
indicating that Tip60 can directly interact with p14ARF (Figure 7A). Furthermore, using two23
16
deletion mutants mapping the entire Tip60 protein, we observed that the 212-513 region of Tip601
containing the HAT domain of the protein was involved in the interaction with p14ARF.2
Conversely, using mutant GST-p14ARF fusion proteins encoding either exon1β (GST-p14ARF1-65) or3
exon 2 (GST-p14ARF65-132) of p14ARF, we observed that in vitro translated HA-Tip60 was retained4
only on GST-p14ARF1-65 beads indicating that exon1β of p14ARF was necessary and sufficient to5
interact with Tip60 (Figure 7B). Importantly, both Tip60 and p14ARF proteins were found to6
interact in vivo when overexpressed in transiently transfected cells (Figure 7C). Taken together7
these data indicate that Tip60 physically interacts with p14ARF. Finally, we investigated whether8
the interaction between p14ARF and Tip60 was required for ATM/CHK2 activation. To do so,9
cells were transiently transfected with plasmids encoding either wild-type p14ARF or truncated10
p14ARF mutants. In this context, we provided evidence that only exon1β of p14ARF (p14ARF 1-65)11
which interacts with Tip60 (Figure 7B) and triggers a G2 arrest in our cells (data not shown), was12
able to induce the accumulation of phospho-ATM(S1981) and phospho-CHK2(Thr68) proteins13
(Figure 7D). Overall, our results demonstrate that Tip60 binding is important for p14ARF-mediated14
ATM/CHK2 activation.15
16
p14ARF is upregulated and required for ATM/CHK2 activation in response to DNA17
alkylating agents and cigarette smoke condensate.18
Our results so far demonstrated the ability of p14ARF to activate ATM/ATR/CHK19
signaling pathways in a model of overexpression. We then attempted to identify some of the20
upstream signals that could trigger p14ARF-mediated activation of these damage pathways in a21
physiological context. Anticancer agents are among the numerous genotoxic insults which22
activate the DNA-damage-response pathway (41). We first tested the effect of several of these23
17
agents on the endogenous p14ARF expression level in the H358 cell line. As shown in figure 8A1
(left panel), treatment with either etoposide or doxorubicin, two topoisomerase inhibitors2
generating DNA double strand breaks, did not affect p14ARF protein expression. In contrast,3
cyclophosphamide and methylmethanesulfonate, two alkylating agents that create interstrand4
DNA crosslinks, were both found to increase p14ARF expression level as compared to untreated5
cells. This induction of p14ARF was correlated with an increase in its mRNA level (Figure 8A,6
right panel). Importantly, p14ARF expression was also induced in normal human lung epithelial7
cells treated with same alkylating drugs (Figure 8B). Because cigarette smoke carcinogens create8
DNA adducts, we investigated the consequence of a cigarette smoke condensate (CSC) cell9
treatment on p14ARF expression. As expected, p14ARF expression level was upregulated in the10
presence of CSC (Figure 8C). Then, we used siRNA to investigate the role of p14ARF induction in11
response to alkylating agents. We showed that p14ARF knocked-down abolished ATM and CHK212
activation induced by cyclophosphamide treatment (Figure 8D), demonstrating the requirement13
of p14ARF for the activation of ATM/CHK2 pathway in response to these drugs. Furthermore, and14
consistent with a major role of Tip60 in the activation of ATM/CHK2 by p14ARF, we also15
observed that Tip60 neutralization prevented ATM and CHK2 activation in cyclophosphamide-16
treated cells as compared to untreated cells, despite p14ARF induction (Figure 8D). Importantly,17
treating cells with cyclophosphamide induced the interaction of endogenous p14ARF and Tip6018
proteins (Figure 8E), confirming in a physiological context that the p14ARF/Tip60 interaction19
participates to the DNA damage response. Altogether, these data demonstrate that p14ARF and20
Tip60 act as two closely components of the DNA damage checkpoint in response to alkylating21
agents.22
18
Direct correlation between p14ARF and P-CHK2(Thr68) expression in human lung1
tumors2
Our present data identify a link between p14ARF and the DNA damage signaling pathway3
in cell lines, and our previous results described the inactivation of p14ARF in human lung tumors4
(15). We therefore asked whether p14ARF expression could correlate with activation of some of5
the components of the DNA damage network in human lung tumors. To this end, we studied6
p14ARF, CHK2 and P-CHK2(Thr68) expression using immunohistochemistry in 72 resected lung7
tumors of different histological types (Figure 9 and Table I). As compared to normal lung8
structures present at the vicinity of the tumors, p14ARF immunostaining was undetectable in 23/729
(32%) human lung tumors, predominantly in NE lung tumors (21/44; 48%) as previously10
reported (15). Moreover, CHK2 expression was observed in 60/72 (83%) human lung tumors. Of11
these 60 CHK2 expressing tumors, 36 (60%) accumulated the active P-CHK2(Thr68) protein. A12
direct correlation linking the expression of both p14ARF and P-CHK2(Thr68) was found in all13
tumors tested (p<0.003) with 43/60 (72%) samples exhibiting either the presence or absence of14
both proteins expression. Interestingly, this direct correlation was also observed in NE tumors15
(p<0.018), which were predominantly negative for both p14ARF and P-CHK2(Thr68) staining16
(11/36 ; 31%) as compared to NSCLC (1/24 ; 4%) (Table I). Taken together, these data are17
consistent with p14ARF being a determinant of CHK2 phosphorylation in human lung tumors.18
19
Discussion20
21
The contribution of p14ARF to the cellular response following treatments with genotoxic22
agents remains a subject of debate. Although some studies assess that p14ARF is not involved in23
19
this process (20, 30, 43), others report that its level increases after exposure to γ-radiation and that1
its loss results in a defective DNA-damage arrest upon ionizing radiation (22, 23). Here, we2
provide evidence that p14ARF expression level is upregulated in cells treated with alkylating3
agents as well as with cigarette smoke condensate, and demonstrate that p14ARF is required for4
activation of ATM and CHK2 in this setting. Therefore, our data are consistent with p14ARF being5
a critical mediator of the DNA damage network.6
One interesting aspect of our study is the ability of p14ARF to activate the ATM/ATR/CHK7
kinases that were so far uniquely ascribed to DNA damage signaling checkpoint. In this context,8
we demonstrated that both CHK1 and CHK2 kinases are required for p14ARF-mediated G29
checkpoint. Importantly, the double inactivation of CHK1 and CHK2 kinases in p14ARF-10
expressing cells leads to apoptosis, suggesting that both kinases could compensate one another,11
ultimately protecting cells from death. They also suggest that CHK1 and -2 cooperate for G212
arrest in phosphorylating distinct targets upon p14ARF expression. Accordingly, we observed that13
Cdc25C phosphorylation was not affected by CHK2 neutralization (data not shown). Similar14
examples of cooperation, in which CHK1 primarily functions in initiating a G2 arrest and CHK215
plays a supporting role in maintaining this arrest, have already been reported in response to DNA16
damage (18, 35). The CHK kinases are the major downstream transducers of the ATM and ATR17
kinases (34). We obtained evidence that both ATM and ATR kinases are activated by p14ARF and18
required for its antiproliferative function. Furthermore we showed that, in response to p14ARF,19
phosphorylation of both CHK1 and CHK2 is altered upon ATM neutralization while ATR20
inhibition affects CHK1 activity only. These data are consistent with previous studies21
demonstrating that ATM phosphorylates CHK1 and CHK2 whereas ATR is considered to date as22
a direct upstream activator of CHK1 only (34). Furthermore, they suggest a mechanism in which23
20
ATM and ATR cooperate to induce G2 arrest, as previously reported in the IR-induced G2/M1
phase checkpoint model (7). Finally we also show that, in a more general context, p14ARF can2
induce the phosphorylation of Mdm2 and p53 on residues specifically targeted in response to3
DNA damage, which could be another way for p14ARF to activate p53. These results are in4
agreement with a recent paper reporting an ATM-dependent activation of p53 by p14ARF (29).5
How p14ARF might activate ATM/ATR signaling pathways? It was very recently6
demonstrated that oncogenic stimuli induce a DNA damage response in human tumors through7
aberrations in DNA replication (5, 16). Interestingly, the Foxm1b and topoisomerase 1 proteins,8
two components of the DNA replication machinery, have been both identified as p14ARF targets9
(10, 21). Therefore, it is possible that p14ARF activates ATM/ATR/CHK signaling pathways by10
affecting replicative processes. However, another plausible explanation for ATM/CHK211
activation by p14ARF comes from the recent notion of ATM activation through epigenetic12
mechanisms (2). Consistent with the implication of some chromatin remodelling enzymes in the13
DNA damage network, we provide evidence that the Tip60 protein is absolutely required for14
p14ARF-mediated activation of ATM/CHK2 pathway in response to DNA injuries and15
demonstrate that a Tip60/p14ARF complex is induced in this context. Importantly, using a large-16
scale RNAi screen, Berns and colleagues previously identified Tip60 as a target gene whose17
suppression conferred resistance to ARF-dependent proliferation arrest (6). Therefore, by18
creating a direct link between p14ARF and Tip60 proteins, our data highlight a model in which19
p14ARF and Tip60 act as two closely components of anti-proliferative pathways. In this context, it20
remains to elucidate the molecular mechanisms by which p14ARF and Tip60 activate ATM/CHK2.21
In view of Bakkenist’s study showing ATM activation following a Trichostatin A cell treatment,22
chromatin remodelling through p14ARF/Tip60 binding could be one of the way for ATM/CHK223
21
activation. In this setting, it is interesting to notice that Drosophila Tip60 was recently involved1
in the exchange of phospho-H2Av with H2Av at DNA lesions (26). Alternatively, modulation of2
Tip60 activity towards non-histone proteins (31, 40) and/or regulation of Tip60 transcriptional3
functions (8) might also be involved in the activation of ATM/CHK2 signaling pathway by4
p14ARF.5
We found a direct correlation between the expression of both p14ARF and phospho-6
CHK2(Thr68) proteins in a large series of human lung tumors. In keeping with our data on cell7
lines, these results confirm that p14ARF is a critical determinant of CHK2 activation. Activation of8
an ATM/CHK2-regulated DNA damage response network was recently identified as a barrier9
against human cancer and genetic instability (4, 5, 12, 16). Therefore, based on our data, we10
propose a model in which p14ARF plays a central role in tumor suppression through activation of11
the DNA damage response (Figure 10). According to this model, p14ARF inactivation would allow12
the tumoral cells to dodge the CHK2-dependent checkpoint control normally activated in13
response to cigarette smoke carcinogens, thus favoring lung tumorigenesis. This hypothesis fits14
perfectly well with the high frequency of p14ARF loss we have previously reported in aggressive15
small cell lung cancers, which are tumors strictly related to tobacco smoking (15).16
17
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Figure legends1
2
Figure 1: Caffeine treatment prevents the antiproliferative effect of p14ARF.3
p14ARF-inducible clones derived from H358 cells were treated for 72 hours in the presence (+) or4
absence (-) of doxycyclin and/or caffeine as indicated. (A) Cell survival was evaluated after5
methylene blue staining. In each case, the growth of cells cultured without doxycyclin in the6
presence or absence of caffeine was normalized to 100%. Results are the mean ± SD of three7
independent experiments performed in duplicate (** P < 0.01; Student t-test). (B, C) Cell-cycle8
and western blot analyses. Representative data of at least three independent experiments are9
shown.10
11
Figure 2: p14ARF activates CHK1/2 kinases12
(A) Phosphorylation of CHK1 and CHK2 proteins was studied by western blotting in p14ARF-13
inducible clones (left panel) or transiently transfected MRC5 human fibroblasts (right panel). (B)14
Equal amounts of CHK1 (left panel) or CHK2 (right panel) protein were immunoprecipitated15
from p14ARF-inducible clones and tested for their ability to phosphorylate a GST-Cdc25C fusion16
protein. Irrelevant mouse (IgGS) and rabbit (IgGR) immunoglobulines were used as negative17
control. Phosphorylation of GST-Cdc25C on its serine 216 residue was assessed by18
immunoblotting. GST or GST-Cdc25C recombinant proteins were detected by immunoblotting19
using an anti-GST antibody (arrows).20
21
22
23
29
Figure 3: Activation of both CHK1 and CHK2 kinases is required for p14ARF-induced cell1
growth inhibition.2
(A, B) p14ARF-inducible clones were transfected with either mismatch or siRNAs specifically3
targeting chk1 and/or chk2 RNAs as indicated and subjected to western blot (left panels) and cell4
cycle analyses (right panels). Apoptosis was detected using immunoblotting with an anti-active5
caspase-3 antibody.6
7
Figure 4: p14ARF activates ATM/ATR pathways to induce G2 arrest8
p14ARF-inducible clone was subjected to western blot analysis using (A) anti-ATR, anti-P-ATM9
(S1981) or anti pS/TQ ATM/ATR antibodies or (B) anti-P-Rad17(Ser645) or -P-H2AX(Ser139)10
(γ-H2AX) antibodies. Treatment with λ-phosphatase (λ-Ppase) before loading confirmed the11
phosphorylation of ATR, ATM and ATM/ATR substrates upon p14ARF expression. (C)12
Immunolocalization of p14ARF (green), pS/TQ ATM/ATR, γ-H2AX and P-Rad17(Ser645) (red)13
proteins was visualized by co-immunofluorescence in the same cells. The p14ARF staining did not14
colocalize with pS/TQ ATM/ATR, γ-H2AX or P-Rad17(Ser645) nuclear foci (merge, yellow).15
(D, E) p14ARF-inducible clones were transfected with either mismatch or atm or atr siRNA and16
subjected to cell cycle (D) and western blot (E) analyses. For cell cycle analysis, results are the17
mean ± SD of three independent experiments.18
19
Figure 5: p14ARF induces the accumulation of phosphorylated p53 and MDM2 proteins.20
(A) A549 cells (p53-proficient) were transfected with empty pCDNA3 or pCDNA3-p14ARF and21
subjected to western blot analysis. (B) MDM2 protein expression and phosphorylation were22
30
analyzed by western blotting in stable p14ARF-inducible clones cultured in the presence (+) or1
absence (-) of doxycyclin for the indicated times.2
3
Figure 6: Tip60 neutralization prevents activation of ATM/CHK pathways by p14ARF.4
p14ARF-inducible clones were transfected with either mismatch or Tip60 siRNA and analyzed for5
ATM, ATR, CHK1, CHK2 and H2A.X activation by western blotting. A relative Tip60 mRNA6
expression level was assessed using RT/PCR as described. Results are representative of three7
independent experiments.8
9
Figure 7: p14ARF/Tip60 interaction is required for ATM/CHK2 activation.10
(A) ”In vitro” translated HA-Tip60 or mutant forms corresponding to the N- or C-terminal parts11
of the protein was subjected to a GST-pull down assay using beads covered with GST or GST-12
p14ARF fusion proteins. Immunoblotting was performed using HA antibody. (B)  ”In vitro”13
translated HA-Tip60 was incubated with GST, GST-p14ARF, GST-p14ARF1-65 or GST-p14ARF66-132-14
coated beads as indicated. GST fusion proteins and bound Tip60 were detected by15
immunoblotting using anti-GST (lower panel, arrows) or anti-HA (upper panel) antibody16
respectively. (C) Immunoprecipitation of p14ARF followed by immunoblotting with anti-HA or17
anti-p14ARF antibodies was performed in COS cells. Inputs represent 10% of total18
immunoprecipitate. (D) H1299 cells were transfected with pcDNA3 or plasmids encoding p14ARF,19
p14ARF1-65-HA or p14ARF66-132-Myc proteins, as indicated. Phosphorylations of ATM and CHK220
were analyzed by western blotting.21
22
31
Figure 8: Alkylating drugs and Cigarette Smoke Condensate (CSC) upregulate p14ARF to1
activate the ATM/CHK2 pathway.2
(A) H358 cells were treated with indicated cytotoxic agents and analyzed for p14ARF expression3
by immunoblotting (left panel) or semi quantitative RT-PCR (right panel). Relative p14ARF4
mRNA level represents the ratio of p14ARF/actin mRNAs. (B) Western blot analysis of p14ARF in5
Normal Human Bronchial Epithelial (NHBE) cells treated with indicated drugs. (C) H358 cells6
were treated with cigarette smoke condensate and analyzed for p14ARF expression by western7
blotting. (D) H358 cells were transfected for 48 hours with either mismatch, p14ARF or Tip608
siRNA and then treated or not for an additional 24 hours with cyclophosphamide (10µM).9
Western blot analyses were performed with the indicated antibodies. (E) Immunoprecipitation of10
endogenous p14ARF and Tip60 proteins was performed in nuclear extracts of H1299 cells treated11
(+) or not (-) with 50 µM cyclophosphamide for 24 hours.12
13
Figure 9: Immunohistochemical analysis of p14ARF, CHK2 and P-CHK2(Thr68) status in14
human lung tumors.15
Upper panels: Small cell lung carcinoma (SCLC) exhibiting negative p14ARF and P-16
CHK2(Thr68) staining and positive CHK2 nuclear expression (magnification x40; bar17
scale=100µm). Lower panels: Squamous lung carcinoma with p14ARF, CHK2 and P-18
CHK2(Thr68) positive staining (magnification x20; bar scale=200µm).19
20
Figure 10: A model for p14ARF-mediated DNA damage response in lung tumors.21
Following exposure to alkylating agents or cigarette smoke condensate, p14ARF is upregulated and22
interacts with the histone acetyl transferase Tip60 to activate an ATM/CHK2-dependent DNA23
32
damage checkpoint. In this context, chromatin remodelling through modulation of1
proteins/histones acetylation might be one of the ways for the cell to point out the presence of2
damaged DNA to the components of checkpoint machineries. Therefore and according to this3
model, inactivation of p14ARF in lung tumors would allow the tumoral cells to dodge the CHK2-4
dependent checkpoint control normally activated in response to cigarette smoke carcinogens, and5
would therefore contribute to the carcinogenesis process. This model does not exclude the6
possibility of oncogene-p14ARF signals mediating ATM/ATR/CHK activation, which are not7
discussed here.8
9
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1
2
3
4
Total no     P-CHK2(Thr68)  +       P-CHK2(Thr68)  -Histological
class of cases p14ARF -  CHK2 +  p14ARF + p14ARF - p14ARF + p14ARF  - P
NSCLC
C
28 2 24 17 1 5 1 NS
NE carcinoma 44 21 36 14 4 7 11 0.018
Total 72 23 60 31 5 12 12 0.003
TABLE 1. Immunohistochemical analysis of p14ARF and phospho-CHK2(Thr68)
proteins in human lung tumors
-: negative immunostaining; +: positive immunostaining. P: statistical analyses were performed
   using a Chi-2 test. NS: non significant.
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